159 related articles for article (PubMed ID: 16008591)
21. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
[TBL] [Abstract][Full Text] [Related]
22. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
23. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants.
Ciancio G; Mattiazzi A; Roth D; Kupin W; Miller J; Burke GW
Clin Transplant; 2003 Oct; 17(5):428-32. PubMed ID: 14703925
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
25. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
Ekberg H; Grinyó J; Nashan B; Vanrenterghem Y; Vincenti F; Voulgari A; Truman M; Nasmyth-Miller C; Rashford M
Am J Transplant; 2007 Mar; 7(3):560-70. PubMed ID: 17229079
[TBL] [Abstract][Full Text] [Related]
26. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
Stratta RJ; Alloway RR; Lo A; Hodge E
Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
[TBL] [Abstract][Full Text] [Related]
27. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
Silverstein DM; Aviles DH; LeBlanc PM; Jung FF; Vehaskari VM
Pediatr Transplant; 2005 Oct; 9(5):589-97. PubMed ID: 16176415
[TBL] [Abstract][Full Text] [Related]
28. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
29. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
30. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
32. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
Nashan B; Light S; Hardie IR; Lin A; Johnson JR
Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
[TBL] [Abstract][Full Text] [Related]
33. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
[TBL] [Abstract][Full Text] [Related]
35. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
[No Abstract] [Full Text] [Related]
36. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
Tran HTB; Acharya MK; McKay DB; Sayegh MH; Carpenter CB; Auchincloss H; Kirkman RL; Milford EL
J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
[TBL] [Abstract][Full Text] [Related]
37. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
[TBL] [Abstract][Full Text] [Related]
38. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
39. Inferior results with basis immunosuppression with sirolimus in kidney transplantation.
van den Akker JM; Hené RJ; Hoitsma AJ
Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636
[TBL] [Abstract][Full Text] [Related]
40. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study.
ter Meulen CG; van Riemsdijk I; Hené RJ; Christiaans MH; Borm GF; van Gelder T; Hilbrands LB; Weimar W; Hoitsma AJ
Am J Transplant; 2004 May; 4(5):803-10. PubMed ID: 15084178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
